In this video, Motley Fool Health-Care Analyst David Williamson breaks down just what happened in the recent Canadian Supreme Court ruling against Pfizer (PFE +4.59%). The Canadian patent on the company's drug Viagra was due to expire in 2014, but the Court struck down the patent in a unanimous ruling, invalidating the patent. Williamson explains the losers and the winners in this situation, and just how much we can expect Pfizer to really be affected.
Canada's Supreme Court unites against Pfizer's Viagra patent.
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid
